An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

• Status: Withdrawn
• Trial end date: 2024-12-31

Summary

This research study is studying a combination of targeted therapies as a possible treatment for multiple myeloma (MM).

The drugs involved in this study are:

• Elotuzumab

• Nivolumab

• Pomalidomide

• Dexamethasone

• Phase: Phase 2

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; BB 1101; Dexamethasone; Dexamethasone acetate; Elotuzumab; Nivolumab; Pomalidomide; Thalidomide